Healthcare News

New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus hormone therapy compared with immediate surgery1Twice as many patients...

Quanta presents positive clinical combination data in KRAS G12D-mutant CRC at ESMO and highlights pan-KRAS progress with advancement of QTX6255

Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmarkDisease control rate of 100% across all response-evaluable patients receiving...

AUSTIN, Texas, 24 oct. 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd’hui que son conseil d’administration avait élu Jan-Paul Simard au poste de co-directeur général, aux...

AUSTIN, Texas, Oct. 24, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) hat heute bekannt gegeben, dass sein Vorstand Jan-Paul Simard mit Wirkung zum 23. Oktober 2026 zum Co-Chief Executive...

In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an...

Chez 24 patients lourdement prétraités atteints de mélanome avancé, dont le cancer était en progression après plusieurs lignes de traitement, y compris des anti-PD1, les données continuent de montrer...

Media ReleaseCOPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated...

RIYADH, Saudi Arabia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is widening patients’ access to emergency expertise beyond its physical...

RIYAD, Arabie saoudite, 24 oct. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre (KFSH) élargit l’accès des patients à l’expertise des services d’urgence au-delà de...